Fig. 2From: Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapyThe dose distributions of (a, b) SPArc and (c, d) RO-IMPT plans for nominal position (solid line) and 20 scenarios of uncertainties (dashed line) for patient 6Back to article page